Epilepsy | Disease Landscape & Forecast | G7 | 2022

Epilepsy, which afflicts approximately 4.7 million people in the major markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s seizure syndrome and seizure type. The epilepsy market has more than 25 antiepileptic drugs (AEDs), most of them generic, that can be effective for many patients as monotherapies or in combination. In this challenging market environment, developers have increasingly targeted underserved, orphan pediatric epilepsy populations, for which several products have been approved in recent years, with more in development. Understanding the trajectory of the established epilepsy market and the evolving competitive landscape in niche segments is critical for marketers of both current and emerging brands to retain market share or carve out a clinical role.

Questions answered

  • What is the state of treatment in epilepsy across the G7, and what needs are left unfulfilled by approved AEDs?
  • What are the market opportunities and sales potential for agents targeting treatment-refractory focal epilepsy patients (e.g., Xcopri) and for agents targeting orphan epilepsy subpopulations (e.g., Epidiolex, Fintepla)?
  • What clinical role will the newer entrants (e.g., Eprontia, Valtoco) and emerging therapies (e.g., Libervant) play in the epilepsy market?
  • How will neurologists differentiate among current and emerging third-generation AEDs, and which of these agents will enjoy the greatest clinical and commercial success in the face of strong generics competition?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: Approximately 20 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other Clarivate research.

Epidemiology: Diagnosed prevalence of epilepsy by country, segmented by generalized and partial-onset seizures; drug-treated cases.

Emerging therapies: Phase II: 8 drugs; Phase III / preregistration: 6 drugs.

Market forecast features: Patient-based market forecast extending through 2031, segmented by brands and generics / biosimilars.

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Login to access report